Who is sponsoring NCT05630937?

NCT05630937 is sponsored by Nerviano Medical Sciences.

What drugs are being tested in NCT05630937?

Interventions in NCT05630937: NMS-01940153E.

What condition does NCT05630937 study?

NCT05630937 studies Unresectable Hepatocellular Carcinoma (HCC).

Is NCT05630937 still recruiting?

NCT05630937 is currently terminated. Last updated 19 June 2025.

Are results published for NCT05630937?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-06-19 · How we verify

NCT05630937

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Terminated Phase 1, PHASE2 Results posted Last updated 19 June 2025

What this trial tests

Phase 1, PHASE2 trial testing NMS-01940153E in Unresectable Hepatocellular Carcinoma (HCC) in 31 participants. Terminated before completion.

Timeline

13 November 2020

Primary endpoint
31 January 2024

6 August 2024

Quick facts

Lead sponsor	Nerviano Medical Sciences
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	13 November 2020
Primary completion	31 January 2024
Estimated completion	6 August 2024
Sites	9 locations across Italy, United States, Spain

Drugs / interventions tested

NMS-01940153E — full drug profile →

Conditions studied

Unresectable Hepatocellular Carcinoma (HCC) — all drugs for Unresectable Hepatocellular Carcinoma (HCC) →

Sponsor

Nerviano Medical Sciences — full company profile →

Who can join

18 and older, any sex, with Unresectable Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Phase I Drug Related Dose Limiting Toxicities (DLTs) Primary · Phase I: From screening to end of first 28-day cycle (17 months)

All 12 Phase I treated patients were evaluable for DLT (Dose-Limiting Toxicity Evaluable Set) and included 6 patients treated at each of the two dose levels explored (i.e., 100 mg/m2/week and 135 mg/m2/week) who received at least 66% of the study drug in the first 28-day cycle of treatment and underwent a DLT assessment within the DLT window. Participants who experienced DLTs are presented.

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	0
135 mg/m2/Week Dose (Phase I)	2

Phase II Objective Response Rate Primary · Phase II: From Phase II start to Study Completion (23 months)

The objective response rate (ORR) was calculated as the proportion of evaluable patients who achieved, as best overall response (BOR), confirmed complete response (CR) or partial response (PR) measured by investigator-assessed RECIST 1.1 (Phase II).

Stable Disease

Group	Value	95% CI
Phase II (Evaluable Population)	3

Progressive Disease

Group	Value	95% CI
Phase II (Evaluable Population)	11

Complete Response

Group	Value	95% CI
Phase II (Evaluable Population)	0

Partial Response

Group	Value	95% CI
Phase II (Evaluable Population)	0

Treatment-emergent Adverse Events by Maximum CTC Grade Secondary · Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)

The maximum Common Terminology Criteria (CTC) grade (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental acti

Grade 1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	0
135 mg/m2/Week Dose (Phase I)	0
Phase II (Evaluable Population)	3

Grade 2

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	1
135 mg/m2/Week Dose (Phase I)	1
Phase II (Evaluable Population)	8

Grade 3

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	3
135 mg/m2/Week Dose (Phase I)	3
Phase II (Evaluable Population)	7

Grade 4

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	1
135 mg/m2/Week Dose (Phase I)	2
Phase II (Evaluable Population)	0

Treatment-emergent Adverse Events Related to NMS-01940153E Secondary · Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)

The number of treatment-emergent adverse events related to NMS-01940153E by maximum CTC grade experienced (graded using NCI CTCAE Version 5.0). Whether the the AE was related or not was assessed by the investigator. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or med

Grade 1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	0
135 mg/m2/Week Dose (Phase I)	0
Phase II (Evaluable Population)	7

Grade 2

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	1
135 mg/m2/Week Dose (Phase I)	1
Phase II (Evaluable Population)	3

Grade 3

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	2
135 mg/m2/Week Dose (Phase I)	2
Phase II (Evaluable Population)	2

Grade 4

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	1
135 mg/m2/Week Dose (Phase I)	2
Phase II (Evaluable Population)	0

Hematology: Overall Treatment-emergent Abnormalities by Dose Level and Maximum CTC Grade Secondary · From screening to 28 days follow-up, an average 6 months

Number of treatment emergent abnormalities (at any grade) at all dose levels are presented. CTC = Common Terminology Criteria WBC = white blood cells

Hemoglobin Decreased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	13
135 mg/m2/Week Dose (Phase I Only)	5
All Treated Participants (Phase I and II; All Dose Levels)	18

Neutrophil Count Decreased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	6
135 mg/m2/Week Dose (Phase I Only)	4
All Treated Participants (Phase I and II; All Dose Levels)	10

WBC Decreased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	8
135 mg/m2/Week Dose (Phase I Only)	6
All Treated Participants (Phase I and II; All Dose Levels)	14

Platelet Count Decreased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	6
135 mg/m2/Week Dose (Phase I Only)	4
All Treated Participants (Phase I and II; All Dose Levels)	10

Neutrophils Count Decrease: Time to First Occurrence of >=Grade 3 and Time to Recovery to Grade 1 Secondary · From screening to 28 days follow-up, an average 6 months

The mean days to first occurrence of neutrophil count decrease are presented for all dose levels. Grade 0: ≥2,000/mm3 Grade 1: ≥1,500-\< 2,000/mm3 Grade 2: ≥1,000- \< 1,500/mm3 Grade 3: ≥500- \< 1,000/mm3 Grade 4: \<500/mm3 * G3 = Time (days) to Treatment Start to First Occurrence of Neutrophil Count Decrease \>=Grade 3 * G3 to Recovery to G1 = Time (days) to First Occurrence of Neutrophil Count Decrease \>= Grade 3 to Recovery to Grade 1

>=G3

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	63.00	± 19.80
135 mg/m2/Week Dose (Phase I Only)	28.00	± 15.36
All Treated Participants (Phase I and II; All Dose Levels)	39.67	± 23.38

>= G3 to Recovery to G1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	7.00	± 1.41
135 mg/m2/Week Dose (Phase I Only)	7.33	± 3.51
All Treated Participants (Phase I and II; All Dose Levels)	7.20	± 2.59

Blood Chemistry: Treatment-emergent Abnormalities by Dose Level Secondary · From screening to 28 days follow-up, an average 6 months

Treatment-emergent abnormalities in blood chemistry at any grade are presented by dose level. ALP = Alkaline phosphatase ALT = Alanine aminotransferase AST = Aspartate aminotransferase GGT = Gamma-glutamyl transferase LDH = Lactate dehydrogenase

Hypoalbuminemia

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	8
135 mg/m2/Week Dose (Phase I Only)	4
All Treated Participants (Phase I and II; All Dose Levels)	12

Hypoglycemia

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	0
135 mg/m2/Week Dose (Phase I Only)	1
All Treated Participants (Phase I and II; All Dose Levels)	1

AST Increased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	12
135 mg/m2/Week Dose (Phase I Only)	3
All Treated Participants (Phase I and II; All Dose Levels)	15

ALT Increased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	8
135 mg/m2/Week Dose (Phase I Only)	2
All Treated Participants (Phase I and II; All Dose Levels)	10

GGT Increased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	9
135 mg/m2/Week Dose (Phase I Only)	1
All Treated Participants (Phase I and II; All Dose Levels)	10

Creatinine Increased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	6
135 mg/m2/Week Dose (Phase I Only)	3
All Treated Participants (Phase I and II; All Dose Levels)	9

Blood Bilirubin Increased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	7
135 mg/m2/Week Dose (Phase I Only)	1
All Treated Participants (Phase I and II; All Dose Levels)	8

ALP Increased

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	10
135 mg/m2/Week Dose (Phase I Only)	1
All Treated Participants (Phase I and II; All Dose Levels)	11

Blood Chemistry and Coagulation: Treatment-emergent Abnormalities Secondary · From screening to 28 days follow-up, an average 6 months

Treatment Emergent abnormalities by dose Level are presented for blood chemistry and coagulation parameters. INR = international normalized ratio LNL = lower normal limit NL = normal limit ULN = upper limit of normal

Hyponatremia: Total

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	4
135 mg/m2/Week Dose (Phase I Only)	2
All Treated Participants (Phase I and II; All Dose Levels)	6

Hyponatremia: Below LNL

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	4
135 mg/m2/Week Dose (Phase I Only)	2
All Treated Participants (Phase I and II; All Dose Levels)	6

Hypokalemia: Total

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	0
135 mg/m2/Week Dose (Phase I Only)	1
All Treated Participants (Phase I and II; All Dose Levels)	1

Hypokalemia: Below LNL

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	0
135 mg/m2/Week Dose (Phase I Only)	1
All Treated Participants (Phase I and II; All Dose Levels)	1

Phosphatemia: Total

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	11
135 mg/m2/Week Dose (Phase I Only)	2
All Treated Participants (Phase I and II; All Dose Levels)	13

Phosphatemia: Above ULN

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	3
135 mg/m2/Week Dose (Phase I Only)	0
All Treated Participants (Phase I and II; All Dose Levels)	3

Phosphatemia: Below LNL

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	7
135 mg/m2/Week Dose (Phase I Only)	2
All Treated Participants (Phase I and II; All Dose Levels)	9

Phosphatemia: Above/Below NL

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I and II)	1
135 mg/m2/Week Dose (Phase I Only)	0
All Treated Participants (Phase I and II; All Dose Levels)	1

Electrocardiogram Abnormalities Secondary · From screening to 28 days follow-up, an average 6 months

The number of participants who experienced electrocardiogram abnormalities are presented.

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I)	0
135 mg/m2/Week Dose (Phase I)	0
Phase II (Evaluable Population)	0

Tmax and Tlast of NMS-01940153E Secondary · Day 1 to Day 15

Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Tmax = Time to maximum observed plasma concentration Tlast = Time of last detectable concentration

Tmax: Day 1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	0.933	± 0.0327
135 mg/m2/Week Dose (Phase I Only)	1.19	± 0.513

Tmax: Day 15

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	1.10	± 0.216
135 mg/m2/Week Dose (Phase I Only)	1.87	± 1.90

Tlast: Day 1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	169	± 3.01
135 mg/m2/Week Dose (Phase I Only)	154	± 39.2

Tlast: Day 15

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	144	± 48.5
135 mg/m2/Week Dose (Phase I Only)	169	± 0.418

Cmax and Clast of NMS-01940153E Secondary · Day 1 to Day 15

Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Cmax = Maximum observed plasma concentration Clast = Last detectable concentration

Cmax: Day 1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	0.754	± 0.174
135 mg/m2/Week Dose (Phase I Only)	1.91	± 0.640

Cmax: Day 15

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	1.35	± 1.10
135 mg/m2/Week Dose (Phase I Only)	1.59	± 1.31

Clast: Day 1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	0.0590	± 0.0191
135 mg/m2/Week Dose (Phase I Only)	0.0840	± 0.0335

Clast: Day 15

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	0.113	± 0.0454
135 mg/m2/Week Dose (Phase I Only)	0.133	± 0.0779

AUClast, AUCweekly, and AUCinf of NMS-01940153E Secondary · From Days 1 to 21 (168 hours after the Day 15 infusion)

Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Infusions occurred on Days 1, 8, and 15. AUClast = Area under the interpolated observed plasma time-concentration curve from infusion start to the last observed plasma concentration AUCweekly = Area under the interpolated observed plasma time-concentration curve from infusion start to 168 hours AUCinf = Area under the interpolated observed plasma time-concentration curve from infusion start extrapolated to infinity based on the last observed plasma concentration

AUClast: Day 1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	20.8	± 4.31
135 mg/m2/Week Dose (Phase I Only)	24.8	± 8.55

AUClast: Day 15

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	30.0	± 9.16
135 mg/m2/Week Dose (Phase I Only)	39.1	± 14.9

AUCweekly: Day 1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	20.8	± 4.35
135 mg/m2/Week Dose (Phase I Only)	25.7	± 7.11

AUCweekly: Day 15

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	32.4	± 6.49
135 mg/m2/Week Dose (Phase I Only)	39.0	± 14.8

AUCinf: Day 1

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	28.7	± 6.88
135 mg/m2/Week Dose (Phase I Only)	37.1	± 14.9

AUCinf: Day 15

Group	Value	95% CI
100 mg/m2/Week Dose (Phase I Only)	48.1	± 19.6
135 mg/m2/Week Dose (Phase I Only)	62.9	± 34.1

Adverse events — posted to ClinicalTrials.gov

Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months). Phase 2 started before Phase 1 completed.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase I: 100 mg/m2/Week

Serious: 1/6 (17%)

Deaths: 5/6

Phase I: 135 mg/m2/Week

Serious: 2/6 (33%)

Deaths: 5/6

Phase II: 100 mg/m2/Week

Serious: 5/18 (28%)

Deaths: 9/18

Serious adverse events (8 terms)

Reaction	System	Phase I: 100 mg/m2/Week	Phase I: 135 mg/m2/Week	Phase II: 100 mg/m2/Week
Disease progression	General disorders	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—
Pathological fracture	Musculoskeletal and connective tissue disorders	—	—	—
Sepsis	Infections and infestations	—	—	—
Device related bacteraemia	Infections and infestations	—	—	—
Device related infection	Infections and infestations	—	—	—
Peritonitis bacterial	Infections and infestations	—	—	—

Other adverse events (79 terms — click to expand)

Reaction	System	Phase I: 100 mg/m2/Week	Phase I: 135 mg/m2/Week	Phase II: 100 mg/m2/Week
Asthenia	General disorders	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—
Blood creatinine increased	Investigations	—	—	—
Hypertension	Vascular disorders	—	—	—
Infusion site reaction	General disorders	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—
Chromaturia	Renal and urinary disorders	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—
Blood bilirubin increased	Investigations	—	—	—
Hypotension	Vascular disorders	—	—	—
Oedema peripheral	General disorders	—	—	—
Pyrexia	General disorders	—	—	—
Non-cardiac chest pain	General disorders	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—
Nausea	Gastrointestinal disorders	—	—	—
Haemoperitoneum	Gastrointestinal disorders	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—
Influenza like illness	General disorders	—	—	—
Platelet count decreased	Investigations	—	—	—
Headache	Nervous system disorders	—	—	—
Ascites	Gastrointestinal disorders	—	—	—
Fatigue	General disorders	—	—	—
Infusion site pain	General disorders	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—
Eczema	Skin and subcutaneous tissue disorders	—	—	—
COVID-19	Infections and infestations	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—
Thrombocytosis	Blood and lymphatic system disorders	—	—	—
Hyperthyroidism	Endocrine disorders	—	—	—
Hypothyroidism	Endocrine disorders	—	—	—
Melaena	Gastrointestinal disorders	—	—	—

Most-reported serious reactions: Disease progression, Anaemia, Neutropenia, Pathological fracture, Sepsis, Device related bacteraemia, Device related infection, Peritonitis bacterial.

Data from ClinicalTrials.gov NCT05630937 adverse events section.

Sponsor's own description

This is a Phase I/II, open-label, non-randomized, multicenter study to explore safety, tolerability and antitumor activity of NMS-01940153E as single agent in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy. The Phase I portion is designed as a dose-escalation study in sequential cohorts of patients aimed to obtain the maximum tolerated dose (MTD) that is defined based on the dose limiting toxicities (DLTs) observed in the first cycle of treatment. The Phase II portion is designed as a two-stage study with an interim analysis for futility and stopping criteria for unacceptable toxicity to assess the antitumor activity of NMS-01940153E in adult patients with unresectable HCC previously treated with systemic therapy measured as objective response rate.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Small-molecule-based targeted therapy in liver cancer.
Ming Y, Gong Y, Fu X, Ouyang X, et al · · 2024 · cited 6× · PMID 39113358 · DOI 10.1016/j.ymthe.2024.08.001
Systemic Therapy for Unresectable Hepatocellular Carcinoma: Current Landscape and Future Directions.
Philippi Z, Reddy KD, Malik S, Al-Khalil Z, et al · · 2025 · cited 1× · PMID 40649773 · DOI 10.3390/ijms26135994

Verify or expand the search:

Other recruiting trials for Unresectable Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07391839 — MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. · Phase 1 · recruiting
NCT07408804 — Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib M · NA · recruiting

Other Nerviano Medical Sciences trials

Trials by the same sponsor.

NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT06931626 — Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer · Phase 1 · recruiting
NCT06549790 — Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT05027594 — Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma · Phase 1 · terminated
NCT04910022 — Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05630937 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nerviano Medical Sciences
Last refreshed: 19 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05630937.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing